• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CT1
Click for more information
0.00% 0.2¢

CONSTELLATION TECHNOLOGIES LIMITED - Announcements

Market Cap $1.474M  ! watchlist Created with Sketch. Add to my watchlist

Constellation Technologies Limited is an Australia-based Internet of things (IoT) and... Constellation Technologies Limited is an Australia-based Internet of things (IoT) and digital solutions company. The Company is focused on offering solutions to market, which leverage cloud, IoT, edge-computing sensors, big data, analytics, machine learning (ML), artificial intelligence (AI) and other advanced technologies. The Company through Callisto offers a range of solutions designed to address various industry needs. These solutions include Food Safety & Compliance, Drugs & Medicine Monitoring, Cold Chain Logistics, and Asset Management. Its Gen3 IoT product line offers IoT devices that can capture critical data points across a range of applications, providing its customers with reliable and flexible solutions that support multiple communication networks and sensor customization. Its MeridianCT is a cloud-based software platform and mobile application, which enables users to have an end-to-end IoT data solution to connect, monitor and visualize their data. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
CT1 Recent Trading Volume24/05/12
CT1 Agenix featured at ChinaBio Partnering Forum 201223/05/12
CT1 Presentation to ChinaBio Partnering Forum 201223/05/12
CT1 Change in substantial holding18/05/12
CT1 Japanese Patent granted for Thromboview TechnologyPRICE SENSITIVE14/05/12
CT1 Letter to Shareholders - Social Media07/05/12
CT1 Agenix launches Social Media campaign07/05/12
CT1 Cleansing Notice01/05/12
CT1 Appendix 3B01/05/12
CT1 Appendix 4C - quarterlyPRICE SENSITIVE30/04/12
CT1 Quarterly Update and Appendix 4C30/04/12
CT1 Funding Agreement provides certaintyPRICE SENSITIVE23/04/12
CT1 Melbourne Investor Presentation29/03/12
CT1 Market Update March 201229/03/12
CT1 Agenix to feature at Investment Event in Melbourne26/03/12
CT1 Investor Briefing Bioshares CEO Transcript with Agenix CEOPRICE SENSITIVE22/03/12
CT1 Market update for presentation to investors and brokers09/03/12
CT1 Half Year Accounts10/02/12
CT1 Appendix 4D Half Year ended 31 December 2011PRICE SENSITIVE10/02/12
CT1 Shareholder Update Q2 201227/01/12
CT1 Appendix 4C - quarterlyPRICE SENSITIVE27/01/12
CT1 CEO Contract renewed for a further 2 yearsPRICE SENSITIVE04/01/12
CT1 Lapse of Options04/01/12
CT1 Appendix 3Y Change of Director's Interest Notice04/11/11
CT1 Appendix 3Y Change of Director's Interest Notice04/11/11
CT1 Appendix 3Y Change of Director's Interest Notice04/11/11
CT1 Appendix 3B04/11/11
CT1 Results of Meeting31/10/11
CT1 Presentation to Shareholders AGM 201131/10/11
CT1 Chairman's Address to Shareholders31/10/11
CT1 Appendix 4C - quarterlyPRICE SENSITIVE31/10/11
CT1 Lapse of Options17/10/11
CT1 New China agreements advance lead drug and new productsPRICE SENSITIVE13/10/11
CT1 Notice of Annual General Meeting/Proxy Form30/09/11
CT1 China hepatitis drug featured at Bio KoreaPRICE SENSITIVE29/09/11
CT1 Bio Korea 2011 Presentation29/09/11
CT1 Annual Report to shareholders28/09/11
CT1 Important Patent Application lodged for Hepatitis B drugPRICE SENSITIVE27/09/11
CT1 ThromboView showcased at International Conference23/09/11
CT1 Preliminary Final ReportPRICE SENSITIVE31/08/11
CT1 Shareholder Update29/07/11
CT1 Appendix 4C - quarterlyPRICE SENSITIVE29/07/11
CT1 Additional link to positive ThromboView study12/07/11
CT1 New paper further validates ThromboViewPRICE SENSITIVE07/07/11
CT1 Appendix 3Y01/07/11
CT1 Amended Appendix 3Y01/07/11
CT1 Appendix 3Y01/07/11
CT1 Update on Capital structure01/07/11
CT1 Lapse of Listed Options01/07/11
CT1 Thromboview to be showcased in China27/06/11
CT1 Peer Review Article validates ThromboviewPRICE SENSITIVE14/06/11
CT1 China - AGX 1009 on track to meet development milestonesPRICE SENSITIVE08/06/11
CT1 Appendix 4C - quarterlyPRICE SENSITIVE29/04/11
CT1 Drawdown on Standby Subscription Agreement12/04/11
CT1 Shareholder Update07/04/11
CT1 Appendix 3B05/04/11
CT1 Details of Company Address31/03/11
CT1 Company Secretary Appointment/Resignation31/03/11
CT1 Change of Share Registry Services23/03/11
AAX +Change of Share Registry Address07/03/11
CT1 Key Patent for Thromboview granted in EUPRICE SENSITIVE03/03/11
CT1 Completion of New Share Offer and Shortfall Rights Issue28/02/11
CT1 Appendix 3B Shortfall Allotment28/02/11
CT1 Appendix 3B Shortfall Allotment18/02/11
CT1 Appendix 4DPRICE SENSITIVE17/02/11
CT1 Half Yearly Accounts17/02/11
CT1 Appendix 4C - quarterlyPRICE SENSITIVE31/01/11
CT1 Investor Presentation24/01/11
CT1 Investor Presentation Update20/01/11
CT1 Securities Trading Policy30/12/10
CT1 Appendix 3B24/12/10
CT1 Final Instalment - China Settlement24/12/10
CT1 Appendix 3B10/12/10
CT1 Appendix 3Y x 3 Late Lodgement07/12/10
CT1 Change in substantial holding06/12/10
CT1 Ceasing to be a substantial holder03/12/10
CT1 Appendix 3B02/12/10
CT1 Completion of Rights Issue - Further Information26/11/10
CT1 Appendix 3B - Convertible Notes26/11/10
CT1 Results of FY2010 AGM26/11/10
CT1 Completion of Rights Issue26/11/10
CT1 Executive Chairman's Address to FY2010 AGM26/11/10
CT1 Appendix 3B - Rights Issue25/11/10
CT1 Conversion of final tranche of Convertible Notes completed25/11/10
CT1 Rights Issue Acceptances and Shortfall22/11/10
CT1 Appendix 3B22/11/10
CT1 Share Offer Opens For New InvestorsPRICE SENSITIVE22/11/10
CT1 Rights Issue Letter to Agenix Shareholders10/11/10
CT1 Appendix 3B in relation to Fortrend Securities03/11/10
CT1 China Scientific Advisory Board Appointment03/11/10
CT1 Notice of Annual General Meeting/Proxy Form26/10/10
CT1 Amended Investor Presentation October 201025/10/10
CT1 Investor Presentation October 201025/10/10
CT1 Appendix 4C - quarterlyPRICE SENSITIVE25/10/10
CT1 Amended Appendix 3B19/10/10
CT1 Replacement Prospectus Timetable18/10/10
CT1 Replacement ProspectusPRICE SENSITIVE18/10/10
CT1 Appendix 3B06/10/10
CT1 Rights Issue and Share Offer AnnouncementPRICE SENSITIVE06/10/10
CT1 ProspectusPRICE SENSITIVE06/10/10
CT1 Recent Trading Volume
24/05/12
CT1 Agenix featured at ChinaBio Partnering Forum 2012
23/05/12
CT1 Presentation to ChinaBio Partnering Forum 2012
23/05/12
CT1 Change in substantial holding
18/05/12
CT1 Japanese Patent granted for Thromboview Technology
14/05/12PRICE SENSITIVE
CT1 Letter to Shareholders - Social Media
07/05/12
CT1 Agenix launches Social Media campaign
07/05/12
CT1 Cleansing Notice
01/05/12
CT1 Appendix 3B
01/05/12
CT1 Appendix 4C - quarterly
30/04/12PRICE SENSITIVE
CT1 Quarterly Update and Appendix 4C
30/04/12
CT1 Funding Agreement provides certainty
23/04/12PRICE SENSITIVE
CT1 Melbourne Investor Presentation
29/03/12
CT1 Market Update March 2012
29/03/12
CT1 Agenix to feature at Investment Event in Melbourne
26/03/12
CT1 Investor Briefing Bioshares CEO Transcript with Agenix CEO
22/03/12PRICE SENSITIVE
CT1 Market update for presentation to investors and brokers
09/03/12
CT1 Half Year Accounts
10/02/12
CT1 Appendix 4D Half Year ended 31 December 2011
10/02/12PRICE SENSITIVE
CT1 Shareholder Update Q2 2012
27/01/12
CT1 Appendix 4C - quarterly
27/01/12PRICE SENSITIVE
CT1 CEO Contract renewed for a further 2 years
04/01/12PRICE SENSITIVE
CT1 Lapse of Options
04/01/12
CT1 Appendix 3Y Change of Director's Interest Notice
04/11/11
CT1 Appendix 3Y Change of Director's Interest Notice
04/11/11
CT1 Appendix 3Y Change of Director's Interest Notice
04/11/11
CT1 Appendix 3B
04/11/11
CT1 Results of Meeting
31/10/11
CT1 Presentation to Shareholders AGM 2011
31/10/11
CT1 Chairman's Address to Shareholders
31/10/11
CT1 Appendix 4C - quarterly
31/10/11PRICE SENSITIVE
CT1 Lapse of Options
17/10/11
CT1 New China agreements advance lead drug and new products
13/10/11PRICE SENSITIVE
CT1 Notice of Annual General Meeting/Proxy Form
30/09/11
CT1 China hepatitis drug featured at Bio Korea
29/09/11PRICE SENSITIVE
CT1 Bio Korea 2011 Presentation
29/09/11
CT1 Annual Report to shareholders
28/09/11
CT1 Important Patent Application lodged for Hepatitis B drug
27/09/11PRICE SENSITIVE
CT1 ThromboView showcased at International Conference
23/09/11
CT1 Preliminary Final Report
31/08/11PRICE SENSITIVE
CT1 Shareholder Update
29/07/11
CT1 Appendix 4C - quarterly
29/07/11PRICE SENSITIVE
CT1 Additional link to positive ThromboView study
12/07/11
CT1 New paper further validates ThromboView
07/07/11PRICE SENSITIVE
CT1 Appendix 3Y
01/07/11
CT1 Amended Appendix 3Y
01/07/11
CT1 Appendix 3Y
01/07/11
CT1 Update on Capital structure
01/07/11
CT1 Lapse of Listed Options
01/07/11
CT1 Thromboview to be showcased in China
27/06/11
CT1 Peer Review Article validates Thromboview
14/06/11PRICE SENSITIVE
CT1 China - AGX 1009 on track to meet development milestones
08/06/11PRICE SENSITIVE
CT1 Appendix 4C - quarterly
29/04/11PRICE SENSITIVE
CT1 Drawdown on Standby Subscription Agreement
12/04/11
CT1 Shareholder Update
07/04/11
CT1 Appendix 3B
05/04/11
CT1 Details of Company Address
31/03/11
CT1 Company Secretary Appointment/Resignation
31/03/11
CT1 Change of Share Registry Services
23/03/11
AAX +Change of Share Registry Address
07/03/11
CT1 Key Patent for Thromboview granted in EU
03/03/11PRICE SENSITIVE
CT1 Completion of New Share Offer and Shortfall Rights Issue
28/02/11
CT1 Appendix 3B Shortfall Allotment
28/02/11
CT1 Appendix 3B Shortfall Allotment
18/02/11
CT1 Appendix 4D
17/02/11PRICE SENSITIVE
CT1 Half Yearly Accounts
17/02/11
CT1 Appendix 4C - quarterly
31/01/11PRICE SENSITIVE
CT1 Investor Presentation
24/01/11
CT1 Investor Presentation Update
20/01/11
CT1 Securities Trading Policy
30/12/10
CT1 Appendix 3B
24/12/10
CT1 Final Instalment - China Settlement
24/12/10
CT1 Appendix 3B
10/12/10
CT1 Appendix 3Y x 3 Late Lodgement
07/12/10
CT1 Change in substantial holding
06/12/10
CT1 Ceasing to be a substantial holder
03/12/10
CT1 Appendix 3B
02/12/10
CT1 Completion of Rights Issue - Further Information
26/11/10
CT1 Appendix 3B - Convertible Notes
26/11/10
CT1 Results of FY2010 AGM
26/11/10
CT1 Completion of Rights Issue
26/11/10
CT1 Executive Chairman's Address to FY2010 AGM
26/11/10
CT1 Appendix 3B - Rights Issue
25/11/10
CT1 Conversion of final tranche of Convertible Notes completed
25/11/10
CT1 Rights Issue Acceptances and Shortfall
22/11/10
CT1 Appendix 3B
22/11/10
CT1 Share Offer Opens For New Investors
22/11/10PRICE SENSITIVE
CT1 Rights Issue Letter to Agenix Shareholders
10/11/10
CT1 Appendix 3B in relation to Fortrend Securities
03/11/10
CT1 China Scientific Advisory Board Appointment
03/11/10
CT1 Notice of Annual General Meeting/Proxy Form
26/10/10
CT1 Amended Investor Presentation October 2010
25/10/10
CT1 Investor Presentation October 2010
25/10/10
CT1 Appendix 4C - quarterly
25/10/10PRICE SENSITIVE
CT1 Amended Appendix 3B
19/10/10
CT1 Replacement Prospectus Timetable
18/10/10
CT1 Replacement Prospectus
18/10/10PRICE SENSITIVE
CT1 Appendix 3B
06/10/10
CT1 Rights Issue and Share Offer Announcement
06/10/10PRICE SENSITIVE
CT1 Prospectus
06/10/10PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
0.2¢ 		Change
0.000(0.00%) 		Mkt cap ! $1.474M
Open High Low Value Volume
0.2¢ 0.2¢ 0.2¢ $9.104K 4.552M

Buyers (Bids)

No. Vol. Price($)
32 23995490 0.1¢
 

Sellers (Offers)

Price($) Vol. No.
0.2¢ 222518 2
View Market Depth
Last trade - 12.55pm 22/11/2024 (20 minute delay) ?
CT1 (ASX) Chart

Top Stories

IP anomaly thrills Cannidah with project extension hopes in QLD

Cannidah Resources has carried out geophysical work at its flagship project in Queensland which highlighted an IP anomaly.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
ASX Market Open: Aussie market to leap on best 'Trump trade' bump since election day | November 22, 2024 The ASX 200 is tipped to rise as much as 1% at open today after Wall Street enjoyed another major @Trump trade” surge buoyed by year-end optimism.The Dow Jones leaped 1.06% amid the U.S. jump, with the S@P 500 following close behind with a 0.53% rise @ a trend the Aussie bou...
Asian Battery Metals uncover second massive sulphide discovery at Mongolia's Oval play Asian Battery Metals Plc has hit another massive sulphide intercept at the North Oval area of its Oval project in Mongolia
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.